Advanced

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

Bois, Andreas du; Kristensen, Gunnar; Ray-Coquard, Isabelle; Reuss, Alexander; Pignata, Sandro; Colombo, Nicoletta; Denison, Ursula; Vergote, Ignace; Del Campo, Jose M and Ottevanger, Petronella, et al. (2016) In The Lancet Oncology 17(1). p.78-89
Abstract
Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has shown activity in phase 2 trials in this setting. We investigated the combination of nintedanib with standard carboplatin and paclitaxel chemotherapy in patients with newly diagnosed advanced ovarian cancer.
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
The Lancet Oncology
volume
17
issue
1
pages
78 - 89
publisher
Elsevier
external identifiers
  • pmid:26590673
  • wos:000367099700044
  • scopus:84955299214
ISSN
1474-5488
DOI
10.1016/S1470-2045(15)00366-6
language
English
LU publication?
yes
id
4fce8636-9eeb-4a2d-ba1c-c7143297e5b1 (old id 8234927)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26590673?dopt=Abstract
date added to LUP
2015-12-06 12:10:02
date last changed
2017-11-05 03:19:05
@article{4fce8636-9eeb-4a2d-ba1c-c7143297e5b1,
  abstract     = {Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has shown activity in phase 2 trials in this setting. We investigated the combination of nintedanib with standard carboplatin and paclitaxel chemotherapy in patients with newly diagnosed advanced ovarian cancer.},
  author       = {Bois, Andreas du and Kristensen, Gunnar and Ray-Coquard, Isabelle and Reuss, Alexander and Pignata, Sandro and Colombo, Nicoletta and Denison, Ursula and Vergote, Ignace and Del Campo, Jose M and Ottevanger, Petronella and Heubner, Martin and Minarik, Thomas and Sevin, Emmanuel and de Gregorio, Nikolaus and Bidziński, Mariusz and Pfisterer, Jacobus and Malander, Susanne and Hilpert, Felix and Mirza, Mansoor R and Scambia, Giovanni and Meier, Werner and Nicoletto, Maria O and Bjørge, Line and Lortholary, Alain and Sailer, Martin Oliver and Merger, Michael and Harter, Philipp},
  issn         = {1474-5488},
  language     = {eng},
  number       = {1},
  pages        = {78--89},
  publisher    = {Elsevier},
  series       = {The Lancet Oncology},
  title        = {Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.},
  url          = {http://dx.doi.org/10.1016/S1470-2045(15)00366-6},
  volume       = {17},
  year         = {2016},
}